Bio-Path Holdings is a biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body via intravenous transfusion. The company’s lead product candidate, Liposomal Grb-2, is in a phase I study for blood cancers; its second drug candidate, also a liposomal antisense drug, is ready clinical evaluation in lymphoma and solid tumors. For more information visit the company’s Web site at www.biopathholdings.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: